Overview

Pharmacokinetics of Elinogrel in Healthy Volunteers and Patients With Mild, Moderate, and Severe Renal Impairment

Status:
Terminated
Trial end date:
2009-12-01
Target enrollment:
Participant gender:
Summary
The purpose of the study is to determine the pharmacokinetics and safety of elinogrel and its metabolite in patients with mild, moderate, and severe renal impairment compared to healthy volunteers.
Phase:
Phase 1
Details
Lead Sponsor:
Portola Pharmaceuticals
Collaborator:
Novartis